Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits

Fluent BioSciences, a cutting-edge life sciences company leading the charge in revolutionizing single-cell analysis through simple, cost-effective, and highly scalable single-cell RNA sequencing solutions is thrilled to announce the award of an NIH Small Business Innovation Research (SBIR) Phase II grant, funded by the National Institute of General Medical Sciences (NIGMS, 2 R44 GM137648). This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.

Prototype million-cell PIPseq kits developed by Fluent BioSciences that enable the profiling of an unprecedented number of cells within a single reaction were recently tested in the laboratory of Samantha Morris at Washington University, St. Louis (WUSTL). The WUSTL team employs single-cell lineage tracing to interrogate how to recreate physiologically accurate cell types with cellular reprogramming. Ultima Genomics sequencing of the prototype million-cell PIPseq data revealed clonal lineage trees with restriction of specific cell reprogramming fates. Leveraging the unmatched scalability of PIPseq with the affordable high-capacity sequencing of Ultima Genomics, WUSTL demonstrated that cellular reprogramming studies can be easily and affordably conducted at scale.

Sample preparation was simple and the scale of the million-cell kit provided impressive power to our single-cell lineage tracing observations.” 

Samantha Morris, Associate Professor, WUSTL

“The collaboration between Fluent BioSciences and Ultima represents a remarkable synergy in pushing the boundaries of single-cell analysis,” said Brian McKernan, CEO of Fluent BioSciences. “This collaboration harnesses the strengths and expertise of both companies to address a critical challenge faced by researchers – the ability to perform single-cell sequencing on larger cell inputs for improved scalability and reduced cost. By eliminating the need for microfluidics devices or chips, the PIPseq technology offers unparalleled flexibility in the scale of beads per sample.”

“We are excited to work with Fluent BioSciences to demonstrate compatibility of PIPseq on Ultima sequencers, optimize library construction for Ultima-specific sequencing, and demonstrate high-capacity single cell analysis across several applications developed by Fluent, including high cell input neuroscience, multi-sample hashing, and complex CRISPR editing applications. “The single-cell market is undergoing another major wave of growth with larger-scale experiments enabled by low-cost sequencing and advancement of single-cell technology”, said Doron Lipson, CSO of Ultima Genomics.

Through this partnership, Fluent BioSciences and Ultima aim to revolutionize the field of single-cell analysis by enabling researchers to unlock deeper insights into cellular mechanisms and disease pathways with unparalleled throughput and accuracy.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Fluent Biosciences. (2024, April 10). Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits. News-Medical. Retrieved on May 25, 2024 from https://www.news-medical.net/news/20240409/Fluent-BioSciences-awarded-NIH-SBIR-grant-to-commercialize-low-cost-million-cell-transcriptome-profiling-kits-powered-by-Ultima-Genomics-sequencing-prototype-kits-now-shipping.aspx.

  • MLA

    Fluent Biosciences. "Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits". News-Medical. 25 May 2024. <https://www.news-medical.net/news/20240409/Fluent-BioSciences-awarded-NIH-SBIR-grant-to-commercialize-low-cost-million-cell-transcriptome-profiling-kits-powered-by-Ultima-Genomics-sequencing-prototype-kits-now-shipping.aspx>.

  • Chicago

    Fluent Biosciences. "Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits". News-Medical. https://www.news-medical.net/news/20240409/Fluent-BioSciences-awarded-NIH-SBIR-grant-to-commercialize-low-cost-million-cell-transcriptome-profiling-kits-powered-by-Ultima-Genomics-sequencing-prototype-kits-now-shipping.aspx. (accessed May 25, 2024).

  • Harvard

    Fluent Biosciences. 2024. Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits. News-Medical, viewed 25 May 2024, https://www.news-medical.net/news/20240409/Fluent-BioSciences-awarded-NIH-SBIR-grant-to-commercialize-low-cost-million-cell-transcriptome-profiling-kits-powered-by-Ultima-Genomics-sequencing-prototype-kits-now-shipping.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.